Loading...
Symbols:
Loading...
Symbols:
Breaking News | Real-time commentary on the market, with links to key sources.
Thursday, August 28 2008
- 11:09 AM GlaxoSmithKline (GSK) signs a deal worth up to $820M with Valeant Pharmaceuticals (VRX) for access to the firm's experimental epilepsy treatments. Glaxo has made several deals with smaller partners to expand its pipeline of experimental medicines .
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »